<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7507004\results\search\disease\results.xml">
  <result pre="Netherlands[9], Children's InstituteUniversity of Cape TownCape TownSouth Africa[10], The South" exact="African" post="Department of Science and Technology â€� National Research Foundation"/>
  <result pre="(ART) for all HIVâ€�positive patients regardless of CD4 count or" exact="disease" post="stage, referred to as â€œEarly Access to ART for"/>
  <result pre="the â€œreal worldâ€� impact of EAAA on care retention and" exact="viral" post="suppression. Methods In this steppedâ€�wedge randomized controlled trial, 14"/>
  <result pre="effects of EAAA on retention in care and retention and" exact="viral" post="suppression combined. Results Between September 2014 and August 2017,"/>
  <result pre="(95% CI: 83 to 88). The 12â€�month combined retention and" exact="viral" post="suppression endpoint rates were 44% (95% CI: 40 to"/>
  <result pre="CI: 1Â·15 to 2Â·21, pÂ =Â 0.005) and retention and" exact="viral" post="suppression combined (HR: 4.88, 95% CI: 2.96 to 8.05,"/>
  <result pre="in retention in care and on the combined retention and" exact="viral" post="suppression provides an important coâ€�benefit of EAAA to HIVâ€�positive"/>
  <result pre="of EAAA to HIVâ€�positive adults themselves, at least in the" exact="short" post="term. Our results from this â€œreal worldâ€� health systems"/>
  <result pre="scaled up for appropriate care management. universal treatment HIV retention" exact="viral" post="suppression Eswatini Subâ€�Saharan Africa antiretroviral therapy Funding Dutch Postcode"/>
  <result pre="National Institute of Aging, NIHP01â€�AG041710 National Institute of Allergy and" exact="Infectious" post="Diseases 10.13039/100000060 R01â€�AI112339R01â€�AI124389 European Commission 10.13039/501100000780 Wellcome Trust 10.13039/100004440"/>
  <result pre="Institute of Aging, NIHP01â€�AG041710 National Institute of Allergy and Infectious" exact="Diseases" post="10.13039/100000060 R01â€�AI112339R01â€�AI124389 European Commission 10.13039/501100000780 Wellcome Trust 10.13039/100004440 Fogarty"/>
  <result pre="In 2018, nearly 38Â million people were living with human" exact="immunodeficiency" post="virus (HIV), of whom 20.64Â million live in subâ€�Saharan"/>
  <result pre="to scale up HIV testing and treatment, the incidence of" exact="HIV infection" post="remains high, with an estimated 1.7Â million newly infected"/>
  <result pre="scale up HIV testing and treatment, the incidence of HIV" exact="infection" post="remains high, with an estimated 1.7Â million newly infected"/>
  <result pre="as Early Assess to ART for All (EAAA) â€&quot; prevents" exact="viral" post="transmission to the uninfected partner in heterosexual HIVâ€�discordant couples"/>
  <result pre="interest in identifying an effective, sustainable approach to reduce the" exact="infection" post="rate. Without this reduction, the number of people needing"/>
  <result pre="trial offers evidence about the â€œrealâ€�worldâ€� impact on retention and" exact="viral" post="suppression under an EAAA approach. This trial is registered"/>
  <result pre="approved by the trialâ€™s Data Safety Monitoring Board, Advisory Board," exact="Primary" post="Research Team and the Eswatini Ministry of Health. The"/>
  <result pre="HIVâ€�positive participants, 18Â years of age or older, with no" exact="mental illness" post="were eligible for the trial. Individuals who had already"/>
  <result pre="received followâ€�up appointments to reâ€�assess ART eligibility and screen for" exact="tuberculosis" post="symptoms in threeâ€�month intervals. Over the course of the"/>
  <result pre="nursing staff with the introduction of EAAA. 2.4 Measurements The" exact="primary" post="endpoints â€&quot; retention in HIV care and viral suppression"/>
  <result pre="Measurements The primary endpoints â€&quot; retention in HIV care and" exact="viral" post="suppression six months or more after ART initiation among"/>
  <result pre="effect of EAAA on a combined endpoint of retention and" exact="viral" post="suppression. The results for several secondary endpoints (ART initiation,"/>
  <result pre="endpoint of retention and viral suppression. The results for several" exact="secondary" post="endpoints (ART initiation, drug resistance, HIV diseases progression, cost"/>
  <result pre="published elsewhere [14, 15, 16]. The operational definitions of the" exact="primary" post="endpoints, retention and viral suppression, were established according to"/>
  <result pre="16]. The operational definitions of the primary endpoints, retention and" exact="viral" post="suppression, were established according to the definitions outlined by"/>
  <result pre="as the date when either nonâ€�retention in care or elevated" exact="viral" post="load (VL) occurred, and survival time was the minimum"/>
  <result pre="to any events qualifying for nonâ€�retention or elevated VL. Unlike" exact="viral" post="suppression, which considers the patients who survived six months"/>
  <result pre="endpoint is a fully randomized endpoint. Table 1 Endpoint definitions" exact="Primary" post="endpoint Definition Additional considerations Retention Participant is classified as"/>
  <result pre="was used as their transfer date or stopped treatment date" exact="Viral" post="suppression Participants were excluded if: They were not retained"/>
  <result pre="or There was no available VL measurement This endpoint assesses" exact="viral" post="suppression conditional on ARTâ€�initiation and retention to 180Â days"/>
  <result pre="suppressed in the future, they were suppressed in the past" exact="Combined" post="retention and viral suppression Defined as: Date when either"/>
  <result pre="future, they were suppressed in the past Combined retention and" exact="viral" post="suppression Defined as: Date when either nonâ€�retention in care"/>
  <result pre="While this combined endpoint was not one of the original" exact="primary" post="endpoints registered for the trial, it offers important insights"/>
  <result pre="[19]. Because there were a small number of facilities randomized," exact="residual" post="confounding is possible. Thus, we conducted multivariableâ€�adjusted analyses, where"/>
  <result pre="we considered known and suspected baseline determinants of retention and" exact="viral" post="suppression, and included those with pÂ 20]. Steptime was"/>
  <result pre="any background time trends related to quality of care or" exact="disease" post="epidemiology did not lead to spurious differences between the"/>
  <result pre="was significant at pÂ 22]. In sensitivity analyses for the" exact="viral" post="suppression endpoint, Fine and Gray competing risk methods were"/>
  <result pre="Sex n (%) Male 695 (34%) 603 (44%) 1298 (38%)" exact="Female" post="1339 (66%) 768 (56%) 2107 (62%) Marital status n"/>
  <result pre="Education n (%) Illiterate/primary 589 (40%) 384 (38%) 973 (39%)" exact="Secondary" post="438 (30%) 362 (36%) 800 (32%) High school 401"/>
  <result pre="TB symptoms n (%) 82 (4%) 66 (5%) 148 (4%)" exact="Viral" post="load (copies/ml) n (%) &amp;lt;1000 229 (12%) 120 (10%)"/>
  <result pre="(13%) 363 (12%) â‰¥100â€š000 661 (35%) 438 (37%) 1099 (36%)" exact="Viral" post="load missing n (%) 150 (7%) 184 (13%) 334"/>
  <result pre="a means of considering the impact of the intervention on" exact="viral" post="suppression with less need for assumptions about those missing"/>
  <result pre="postâ€�ART initiation and end of followâ€�up, significant improvements of increased" exact="viral" post="suppression were also observed with EAAA compared to SoC"/>
  <result pre="27]. At one year, the cumulative incidence of retention and" exact="viral" post="suppression was 44% (95% CI: 40 to 48) under"/>
  <result pre="3). Table 3 The effect of EAAA on retention and" exact="viral" post="suppression six months post ART initiation Population Control Intervention"/>
  <result pre="1.79 (1.20 to 2.66) 0.004 1.84 (1.28 to 2.65)c 0.0009" exact="Viral" post="suppression six months post ART initiation All enrolled participants"/>
  <result pre="16.18 (8.31 to 31.51) &amp;lt;0.0001 30.86 (8.89 to 107.20)f &amp;lt;0.0001" exact="Combined" post="retention and viral suppression All enrolled participants 723 1649.8"/>
  <result pre="31.51) &amp;lt;0.0001 30.86 (8.89 to 107.20)f &amp;lt;0.0001 Combined retention and" exact="viral" post="suppression All enrolled participants 723 1649.8 0.44 516 1332.2"/>
  <result pre="25 to &amp;lt;30, â‰¥30), screened for TB symptoms (yes, no)," exact="viral" post="load (&amp;lt;5000, 5000 to 30â€š000, &amp;gt;30â€š000), treatment support (yes,"/>
  <result pre="25 to &amp;lt;30, â‰¥30), screened for TB symptoms (yes, no)," exact="viral" post="load (&amp;lt;5â€š000, 5â€š000 to 30â€š000, &amp;gt;30â€š000), access to HIV"/>
  <result pre="was strong evidence of similar rates of improvement in retention," exact="viral" post="suppression at six months or more after ART initiation,"/>
  <result pre="estimated effect sizes and significance levels for both retention and" exact="viral" post="suppression increased after multivariable adjustment (TableÂ 3). In our"/>
  <result pre="with VL measured after baseline, the effect of EAAA on" exact="viral" post="suppression and ability to provide VL measurements six months"/>
  <result pre="the original approach. These two results can be considered an" exact="upper" post="and lower bound on the effectiveness of EAAA on"/>
  <result pre="approach. These two results can be considered an upper and" exact="lower" post="bound on the effectiveness of EAAA on viral suppression"/>
  <result pre="upper and lower bound on the effectiveness of EAAA on" exact="viral" post="suppression six months post ART initiation among those retained."/>
  <result pre="as unsuppressed VLs. Clearly, the strong effect of EAAA on" exact="viral" post="suppression was both a function of the EAAA itself"/>
  <result pre="analysis for this endpoint produced HRs materially unchanged from the" exact="primary" post="analysis (data not shown). Furthermore, in sensitivity analysis for"/>
  <result pre="VLs, there was still an increased rate of retention and/or" exact="viral" post="suppression associated with EAAA. Finally, after consideration of multiple"/>
  <result pre="the three endpoints by covariates (FiguresÂ S6,S7,S8 and TablesÂ S1,S2,S3)." exact="Viral" post="suppression and the combined endpoint varied significantly by facility"/>
  <result pre="We did not assess effect modification by clinic for the" exact="viral" post="suppression endpoint because some clinics had no participants available"/>
  <result pre="of EAAA on the critical endpoints of ART retention and" exact="viral" post="suppression in a â€œrealâ€�worldâ€� public sector health system setting"/>
  <result pre="a â€œrealâ€�worldâ€� public sector health system setting in subâ€�Saharan Africa." exact="Increased" post="retention and viral suppression at six months or more"/>
  <result pre="sector health system setting in subâ€�Saharan Africa. Increased retention and" exact="viral" post="suppression at six months or more after ART initiation"/>
  <result pre="60% increase in retention rates and â€&quot; when considering documented" exact="viral" post="load â€&quot; a fivefold increase in retention and viral"/>
  <result pre="documented viral load â€&quot; a fivefold increase in retention and" exact="viral" post="suppression combined. VL suppression can be considered a proxy"/>
  <result pre="these antiâ€�conservative assumptions, while the estimates we provided in our" exact="primary" post="analysis may be much closer to the reality and"/>
  <result pre="care as an explanation for the large observed increase in" exact="viral" post="suppression among the EAAA group. Lessons learned from this"/>
  <result pre="a relatively high proportion of missing VL measurements. In the" exact="primary" post="analysis, we treated all missing VLs as detectable. If"/>
  <result pre="equivalent to being unsuppressed from health systems, patient safety and" exact="disease" post="transmission standpoints. Under the national guidelines, VLs are not"/>
  <result pre="results from public sector ART programmes in six other subâ€�Saharan" exact="African" post="countries [36]. Anecdotally reported reasons for the relatively poor"/>
  <result pre="causal evidence for the benefits of EAAA on retention and" exact="viral" post="suppression, both for those who were already eligible for"/>
  <result pre="information Figure S1. Definition of nonâ€�retention. Figure S2. Definition of" exact="viral" post="suppression. Figure S3. Kaplanâ€�Meier curves for viral suppression. (a)"/>
  <result pre="S2. Definition of viral suppression. Figure S3. Kaplanâ€�Meier curves for" exact="viral" post="suppression. (a) all participants, (b) SoC ineligible and (c)"/>
  <result pre="eligible. Figure S4. Kaplanâ€�Meier curves for combined endpoint, retention and" exact="viral" post="suppression. (a) all participants, (b) above SoC and (c)"/>
  <result pre="Figure S7. Forest plot of the intervention effect modification for" exact="viral" post="suppression, by covariates. Figure S8. Forest plot of the"/>
  <result pre="participants, by preâ€�specified subgroups. Table S2. Effect of EAAA on" exact="viral" post="suppression six months or more after ART initiation among"/>
  <result pre="preâ€�specified subgroups Table S3. Effect of EAAA on retention and" exact="viral" post="suppression among all participants, by preâ€�specified subgroups LINK Click"/>
  <result pre="Initiative (CHAI), the Eswatini National Network of People Living with" exact="HIV/AIDS" post="(SWANNEPHA), the Southern African AIDS Information Dissemination Service (SAfAIDS),"/>
  <result pre="National Network of People Living with HIV/AIDS (SWANNEPHA), the Southern" exact="African" post="AIDS Information Dissemination Service (SAfAIDS), the South African Centre"/>
  <result pre="the Southern African AIDS Information Dissemination Service (SAfAIDS), the South" exact="African" post="Centre for Epidemiological Modelling and Analysis (SACEMA) and University"/>
  <result pre="for VL testing; and British Columbia Centre for Excellence in" exact="HIV/AIDS" post="for genotype testing. The MaxART Consortium thanks the many"/>
  <result pre="ChenYQ, McCauleyM, GambleT, HosseinipourMC, KumarasamyN, et al. Prevention of HIVâ€�1" exact="infection" post="with early antiretroviral therapy. N Engl J Med. 2011;375(9):830â€&quot;9."/>
  <result pre="KadimaE, et al. Universal testing, expanded treatment, and incidence of" exact="HIV infection" post="in Botswana. N Engl J Med. 2019;381(3):230â€&quot;42.31314967 5HayesRJ, DonnellD,"/>
  <result pre="et al. Universal testing, expanded treatment, and incidence of HIV" exact="infection" post="in Botswana. N Engl J Med. 2019;381(3):230â€&quot;42.31314967 5HayesRJ, DonnellD,"/>
  <result pre="McGrathN, IwujiC, PlazyM, ThiÃ©bautR, et al. Temporal trends of population" exact="viral" post="suppression in the context of Universal Test and Treat:"/>
  <result pre="the ANRS 12249 clusterâ€�randomized trial and associated population cohort. Curr" exact="HIV/AIDS" post="Rep. 2020;17:97â€&quot;108.32072468 9collab: Kingdom of Eswatini . Preliminary findings"/>
  <result pre="et al. Retention in care: a challenge to survival with" exact="HIV infection." post="Clin Infect Dis. 2007;44(11):1493â€&quot;9.17479948 13GrinsztejnB, HosseinipourMC, RibaudoHJ, SwindellsS, EronJ,"/>
  <result pre="2016;11(1):102â€&quot;108.26545266 27HaberN, TanserF, BorJ, NaiduK, MutevedziT, HerbstK, et al. From" exact="HIV infection" post="to therapeutic response: a populationâ€�based longitudinal HIV cascadeâ€�ofâ€�care study"/>
  <result pre="27HaberN, TanserF, BorJ, NaiduK, MutevedziT, HerbstK, et al. From HIV" exact="infection" post="to therapeutic response: a populationâ€�based longitudinal HIV cascadeâ€�ofâ€�care study"/>
  <result pre="et al. A decade of sustained geographic spread of HIV" exact="infections" post="among women in Durban, South Africa. BMC Infect Dis."/>
  <result pre="KimAA, EllenbergerD, ZhangG, et al. Progress with Scaleâ€�Up of HIV" exact="Viral" post="Load Monitoring â€� Seven Subâ€�Saharan African Countries, January 2015â€�June"/>
  <result pre="with Scaleâ€�Up of HIV Viral Load Monitoring â€� Seven Subâ€�Saharan" exact="African" post="Countries, January 2015â€�June 2016. MMWR Morb Mortal Wkly Rep."/>
  <result pre="treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and" exact="viral" post="suppression in East Africa. JAMA. 2017;317(21):2196â€&quot;206.28586888"/>
 </snippets>
</snippetsTree>
